Physician profile
John Mark Mhoon
NPI 1013077510
$5,164.81
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $432 · 2021: $3.82 · 2022: $195 · 2023: $1,891 · 2024: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.50 |
| Education | $284.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $977.52 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Janssen Biotech, INC. | $645.54 | 2019-2024 | Erleada |
| Sumitomo Pharma America, INC. | $501.07 | 2023-2024 | Gemtesa, Orgovyx |
| Abbvie INC. | $474.54 | 2019-2024 | |
| Pfizer INC. | $384.44 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $249.56 | 2019-2024 | Provenge |
| Boston Scientific Corporation | $202.35 | 2019-2024 | Rezum Generator, Spaceoar Vue System - 10ml, Moses 550 Dfl |
| Bayer Healthcare Pharmaceuticals INC. | $185.34 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $140.82 | 2023-2024 | Lynparza |
| Urogen Pharma, INC. | $136.49 | 2022-2024 | Jelmyto |
| Sun Pharmaceutical Industries INC. | $135.63 | 2019-2024 | Yonsa |
| Accord Healthcare, INC. | $113.39 | 2023-2024 | |
| Tolmar, INC. | $104.11 | 2023-2024 | |
| Allergan, INC. | $103.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $101.74 | 2023-2024 | Keytruda, Lynparza, Welireg |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mhoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.